Report of Foreign Issuer (6-k)
May 24 2018 - 3:06PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May, 2018
Commission File Number: 001-35892
GW PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign House
Vision Park
Histon
Cambridge CB24 9BZ
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Notification and public disclosure of
transactions by persons discharging
managerial responsibilities and persons
closely associated with them
1.
|
Details of the person discharging managerial responsibilities / person closely associated
|
a.
|
Name
|
Volker Knappertz
|
2.
|
Reason for the notification
|
a.
|
Position/status
|
Chief Medical Officer
|
b.
|
Initial notification
/Amendment
|
Initial notification
|
3.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a.
|
Name
|
GW Pharmaceuticals PLC
|
b.
|
LEI
|
|
4.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
a.
|
Description of the
Financial instrument, type of instrument
Identification code
|
American Depositary Shares
ISIN: 36197T1034
|
b.
|
Nature of the transaction
|
Sell to cover transaction resulting in exercise of Long Term Incentive Plan options over 1,012 American Depositary Shares (ADSs) followed by sale of 331 ADSs to cover tax liability. Remaining 681 ADSs have been retained.
|
c.
|
Price(s) and volume(s)
|
Price(s)
$153.63
|
Volume(s)
331
|
ADS’s sold
|
d.
|
Aggregated information
·
Aggregated
volume
·
Price
|
n/a
|
e.
|
Date of the transaction
|
May 18, 2018
|
f.
|
Place of the transaction
|
Nasdaq, New York
|
Notification and public disclosure of
transactions by persons discharging
managerial responsibilities and persons
closely associated with them
1.
|
Details of the person discharging managerial responsibilities / person closely associated
|
a.
|
Name
|
Scott Giacobello
|
2.
|
Reason for the notification
|
a.
|
Position/status
|
Chief Financial Officer
|
b.
|
Initial notification
/Amendment
|
Initial notification
|
3.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a.
|
Name
|
GW Pharmaceuticals PLC
|
b.
|
LEI
|
|
4.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
a.
|
Description of the
Financial instrument, type of instrument
Identification code
|
American Depositary Shares
ISIN: 36197T1034
|
b.
|
Nature of the transaction
|
Sell to cover transaction resulting in exercise of Long Term Incentive Plan options over 678 American Depositary Shares (ADSs) followed by sale of 231 ADSs to cover tax liability. Remaining 447 ADSs have been retained.
|
c.
|
Price(s) and volume(s)
|
Price(s)
$153.51
|
Volume(s)
231
|
ADS’s sold
|
d.
|
Aggregated information
·
Aggregated
volume
·
Price
|
n/a
|
e.
|
Date of the transaction
|
May 18, 2018
|
f.
|
Place of the transaction
|
Nasdaq, New York
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
GW Pharmaceuticals plc
|
|
|
|
|
By:
|
/s/ Adam George
|
|
Name:
|
Adam George
|
|
Title:
|
Secretary
|
|
|
|
Date: May 24, 2018
|
|
|